The case for high-dose adjuvant chemotherapy in breast cancer: (I) theoretical considerations
- 31 October 1996
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 22 (5) , 540-542
- https://doi.org/10.1016/s0748-7983(96)93201-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Sequential or Alternating Doxorubicin and CMF Regimens in Breast Cancer With More Than Three Positive NodesJAMA, 1995
- Parametric survival analysis of adjuvant therapy for stage II breast cancerCancer, 1994
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Adjuvant Systemic Therapy and Survival after Breast CancerNew England Journal of Medicine, 1994
- A model of long-term survival following adjuvant therapy for stage 2 breast cancerBritish Journal of Cancer, 1993
- Assessing the impact of adjuvant therapy on cure rate for stage 2 breast carcinomaBritish Journal of Cancer, 1993
- Kinetic Concepts in the Treatment of Breast CancerPublished by Springer Nature ,1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980